As of 10:20am ET
| +0.025 / +2.38%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 8.00, with a high estimate of 11.00 and a low estimate of 2.00. The median estimate represents a +644.19% increase from the last price of 1.08.
The current consensus among 6 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since February, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.